Summit Crumbles After FDA Rejects Merck-Rivaling Lung Cancer Drug

Résumé détaillé
Summit Therapeutics stock crashed Monday after the Food and Drug Administration rejected its Merck-rivaling lung cancer drug, ivonescimab. The post Summit Crumbles After FDA…
Summit Therapeutics (SMMT) stock crashed Monday after the Food and Drug Administration rejected its Merck (MRK)-rivaling lung cancer drug, ivonescimab. Leerink Partners analyst Daina Graybosch wasn't surprised, noting the FDA said ivonescimab in combination with chemotherapy would need to improve overall survival to win approval. Overall survival is how long patients live before dying of any cause. The regimen failed…
Début de l'article, extrait de Investor's Business Daily. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.investors.com)